Le Lézard
Classified in: Health, Science and technology
Subjects: WOM, FDA

FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture


SILVER SPRING, Md., April 9, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration today approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture). These are women with a history of osteoporotic fracture or multiple risk factors for fracture, or those who have failed or are intolerant to other osteoporosis therapies.

U.S. Food and Drug Administration (FDA) logo (PRNewsfoto/FDA)

More than 10 million people in the U.S. have osteoporosis, which is most common in women who have gone through menopause. People with osteoporosis have weakened bones that are more likely to fracture.

"Today's approval provides women with postmenopausal osteoporosis who are at high risk of fracture with a new treatment that will reduce this risk," said Hylton V. Joffe, M.D, M.M.Sc., director of the Center for Drug Evaluation and Research's Division of Bone, Reproductive and Urologic Products. "But Evenity may increase the risk of heart attack, stroke and cardiovascular death so it's important to carefully select patients for this therapy, which includes avoiding use in patients who have had a heart attack or stroke within the previous year."

Evenity is a monoclonal antibody that blocks the effects of the protein sclerostin and works mainly by increasing new bone formation. One dose of Evenity consists of two injections, one immediately following the other, given once a month by a health care professional. The bone forming effect of Evenity wanes after 12 doses so more than 12 doses should not be used. If osteoporosis therapy is needed after the 12 doses, patients should begin an osteoporosis treatment that reduces bone breakdown.

The safety and efficacy of Evenity were demonstrated in two clinical trials involving a total of more than 11,000 women with postmenopausal osteoporosis. In the first trial, one year of treatment with Evenity lowered the risk of a new fracture in the spine (vertebral fracture) by 73% compared to placebo. This benefit was maintained over the second year of the trial when Evenity was followed by one year of denosumab (another osteoporosis therapy) compared to placebo followed by denosumab. In the second trial, one year of treatment with Evenity followed by one year of alendronate (another osteoporosis therapy) reduced the risk of a new vertebral fracture by 50% compared to two years of alendronate alone. Evenity followed by alendronate also reduced the risk of fractures in other bones (nonvertebral fractures) compared to alendronate alone.

Evenity increased the risk of cardiovascular death, heart attack and stroke in the alendronate trial, but not in the placebo trial. Therefore, Evenity contains a boxed warning on its labeling stating that it may increase the risk of heart attack, stroke and cardiovascular death and should not be used in patients who have had a heart attack or stroke within the previous year. Health care professionals should also consider whether the benefits of Evenity outweigh its risks in those with other risk factors for heart disease and should discontinue Evenity in any patient who experiences a heart attack or stroke during treatment.

Common side effects of Evenity included joint pain and headache. Injection site reactions were also observed.

The FDA granted the approval of Evenity to Amgen.

For more information:

Osteoporosis: Common treatments

How long should you take certain osteoporosis drugs?

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency is also responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Lyndsay Meyer, 240-402-5345, lyndsay.meyer@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration


These press releases may also interest you

at 20:30
Silicon Valley-based firm announced Founder/CEO Leslie Magsalay-Zeller transforms Pooki's Mahi® manufacturing into a "Digital Beverage Supply Chain" by enforcing a Just-In-Time (JIT) operations model for an FDA certified facility. The technology...

at 20:02
Viral Vector & Plasmid DNA Manufacturing Market: OverviewThis report analyzes the current and future scenario of the global viral vector & plasmid DNA manufacturing market for the period 2019 to 2027. Increase in prevalence and incidence rates of...

at 20:02
Global payment processing solutions market size to grow at a CAGR of 10.4% during the forecast periodRead the full report: https://www.reportlinker.com/p05777743/?utm_source=PRN The global payment processing solutions market is expected to grow from...

at 20:02
Laser sensor market to grow at CAGR of 10.0% from 2019 to 2024The laser sensor market is expected to grow from USD 535 million in 2019 to USD 863 million by 2024?growing at a CAGR of 10.0% during the forecast period. The laser sensor market has been...

at 20:02
Exponential rise and sophistication of cyber-attacks and cumbersome administration after threat detection to drive the overall SOC as a service marketRead the full report: https://www.reportlinker.com/p05777741/?utm_source=PRN The global SOC as a...

at 20:00
Running Remote, the world's largest remote work conference, announces Running Remote 2019 in Bali, Indonesia. The conference boasts over 24 inspirational remote company industry leaders and innovators ready to share practical and actionable advice...



News published on 9 april 2019 at 15:06 and distributed by: